4 July 2021
Hi Dr. Sharpless,
I read your April 2021 talk to the American Association for Cancer Research (AACR), see
http://www.natpernick.com/AACRSharplessApril2021.pdf, and am distributing it to my
network.
In my view, reducing the high number of US cancer deaths is primarily a management
problem to be solved by creating a strategic plan that identifies necessary management and
medical / scientific tasks:
1. Our goal should be to reduce annual US cancer deaths from 600,000 currently to 100,000
by 2030, as discussed in our strategic plan,
http://www.natpernick.com/StrategicPlanCuringCancer.html. Although your goal of
reducing age-adjusted cancer death rates in half is rational, this is too abstract to resonate
with the hundreds of millions of Americans who must feel compelled to act.
2. I believe that we can substantially increase survival for aggressive pancreatic, lung,
colorectal and breast cancers by using large combinations of partially effective therapies
targeting different malignant attributes. For each cancer histological type, we should identify
20-30 important malignant attributes and then identify or develop therapies with at least
partial effectiveness for each attribute, see
http://natpernick.com/Pancreatic%20Cancer%20Treatment%20Targets.html. Then, our
oncologists and pharmacologists can find combinations of 8-10 of these therapies that will be
substantially effective, http://www.natpernick.com/CombinationsOfTherapy.html. This
proposal is based on complexity science – the behavior of the whole is greater than the
behavior of the sum of the parts. We should also reduce the number of clinical studies using
only single agents (after initial trials establish their efficacy) – we know that single agents
typically cannot be successful because they cannot adequately damage the weblike nature
of the malignant process.
3. To determine the malignant attributes of each cancer histological type, we need to identify
systemic network disturbances that nurture the cancer, such as microenvironmental factors,
inflammation, unicellular-type programming, dysfunctional immune systems and hormones.
We also have to better understand cancer cell stability (“cancer attractors”,
https://pubmed.ncbi.nlm.nih.gov/19595782) and how to disrupt it with therapies that move
tumor cells into less hazardous networks, https://pubmed.ncbi.nlm.nih.gov/31921665.